NPHLA Intelligence
Thursday, October 1, 2026Updated Oct 1, 2026, 12:05 PM EDT
Professional intelligence from official records, research and the industry’s reporting. Every briefing shows its sources. Information, never medical or legal advice.
Top story
Every new official record on the Metabolic & Weight-Loss Intelligence desk since this morning, each linked to its primary source.
NPHLA tracked 29 new official records on this desk today: 20 trial updates, 9 new studies.
Why it matters: GLP-1 and obesity-medicine developments can change access, supply, clinical evidence and patient conversations for clinics, pharmacies and prescribers.
Every new official record on the AI, Technology & Practice Growth desk since this morning, each linked to its primary source.
Automated from official records10 sources1 min read
Every new official record on the Aesthetics, Regenerative & Longevity Medicine desk since this morning, each linked to its primary source.
Automated from official records13 sources1 min read
Every new official record on the Pharmacy, Compounding & Regulatory Intelligence desk since this morning, each linked to its primary source.
Automated from official records6 sources1 min read
Phase 2, The Methodist Hospital Research Institute. Conditions: Endometrial Atypical Hyperplasia; Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia; Endometrial Cancer Stage I; Endometrial Cancer; Fertility-Sparing Treatment (FST); Obesity & Overweight. I…
Phase 3, Eli Lilly and Company. Conditions: Type 2 Diabetes. Interventions: Orforglipron; Placebo. Investigational: trial-stage therapies are not approved for the use studied.
Esbjerg Hospital - University Hospital of Southern Denmark. Conditions: Bone Disease, Metabolic; Diabetes Mellitus, Type 2; Obesity and Obesity-related Medical Conditions. Investigational — not approved for the use studied.
yifang zhu. Conditions: Acute Ischemic Stroke (AIS). Investigational — not approved for the use studied.
Boehringer Ingelheim. Conditions: Metabolic Dysfunction Associated Steatohepatitis (MASH); Liver Fibrosis. Investigational — not approved for the use studied.
Rijnstate Hospital. Conditions: Atrial Fibrillation; Obesity; Weight Loss. Investigational — not approved for the use studied.
Research summaries link to PubMed records. A single study rarely settles a clinical question.
The FDA, the Federal Register, ClinicalTrials.gov, PubMed and other primary records are monitored around the clock — by servers, not people’s laptops.
Each briefing ends with a numbered Source File. Facts link to the record they come from, and source types are labelled.
AI helps draft briefings from the sources. Sensitive topics — dosing, safety, legal interpretation, named businesses — always go to an NPHLA editor.
If nothing meaningful happened, we publish nothing new. Corrections are shown openly, and published stories are never silently rewritten.
NPHLA Daily · The NPHLA Week
A short weekday briefing at 6 a.m. Eastern and a Monday wrap-up of the week. Members can tailor desks and alerts in their account.
Already a member? Manage your Intelligence emails.
